Compare stocks
Evaluate stocks side by side, to find the best fit for your investment goals.
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
View stockAbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
View stockPerformance
CumulativeRolling yearsLump sum investment
Invest in $IRIX or $ABBV on Lightyear
Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.